Ernexa Therapeutics Inc. (NASDAQ:ERNA – Get Free Report) was the target of a large increase in short interest during the month of October. As of October 30th, there was short interest totaling 33,263 shares, an increase of 67.3% from the October 15th total of 19,877 shares. Currently, 2.0% of the shares of the company are short sold. Based on an average daily volume of 16,424 shares, the short-interest ratio is presently 2.0 days.
Ernexa Therapeutics Stock Up 4.5%
Shares of ERNA traded up $0.07 during mid-day trading on Monday, hitting $1.75. 16,597 shares of the company’s stock were exchanged, compared to its average volume of 625,285. Ernexa Therapeutics has a 52 week low of $1.67 and a 52 week high of $38.02. The stock’s 50-day simple moving average is $2.75 and its 200-day simple moving average is $6.21. The firm has a market cap of $2.97 million, a price-to-earnings ratio of -0.14 and a beta of 2.75.
Ernexa Therapeutics (NASDAQ:ERNA – Get Free Report) last issued its quarterly earnings results on Friday, November 6th. The company reported ($1.89) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.84) by $1.95. Analysts forecast that Ernexa Therapeutics will post -18.02 earnings per share for the current fiscal year.
Analysts Set New Price Targets
A number of brokerages have commented on ERNA. Wall Street Zen lowered Ernexa Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Ernexa Therapeutics in a report on Thursday, October 15th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $30.00.
Get Our Latest Stock Analysis on ERNA
About Ernexa Therapeutics
Ernexa Therapeutics, formerly known as Eterna Therapeutics, is a biotechnology company focused on developing cell therapies for cancer. Its research centers on engineering cells to deliver therapeutic agents within tumors. The company’s lead program, ERNA-101, is an investigational therapy based on allogeneic mesenchymal stem cells engineered to produce interleukin-12, an immune-signaling protein. The approach is intended to concentrate immune activity in the tumor environment. ERNA-101 remains in development, and Ernexa does not have an approved product.
Further Reading
- Five stocks we like better than Ernexa Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Ernexa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ernexa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
